Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
Sponsor: Arog Pharmaceuticals, Inc.
ClinicalTrials ID:NCT03250338
This study evaluates crenolanib's efficacy in relapsed/refractory AML with FLT3 mutations. Eligible participants are adults (18-75) with confirmed AML, FLT3-ITD/D835 mutations, and adequate organ function. Interventions include crenolanib or placebo with chemotherapy regimens (HAM, FLAG-Ida) involving cytarabine, mitoxantrone, fludarabine, idarubicin, and G-CSF.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.
Eligibility Criteria
Inclusion Criteria
- Confirmed diagnosis of AML according to World Health Organization (WHO) 2016 classification
- Presence of FLT3-ITD and/or D835 mutation(s)
- Subjects must be primary refractory or relapsed to 1st line intensive treatment for AML or refractory or relapsed after second line of treatment for AML
- Age ≥ 18 years and ≤ 75 years
- Adequate hepatic function
- Adequate renal functions
- ECOG performance status ≤ 3
Exclusion Criteria
- Known clinically active central nervous system(CNS) leukemia
- Severe liver disease
- Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Prior anti-leukemia therapy within the 14 days prior to randomization. Prior use of quizartinib or gilteritinib must be discontinued 21 days prior to randomization. Prior use of hydroxyurea or other palliative treatment for leukocytosis is allowed.
- Previous treatment with crenolanib or prior participation in clinical trial involving crenolanib.
Get This Program In Your Inbox
You can sign up and apply your patients for this program.